Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

SAB Biotherapeutics, Inc. - Warrant (NQ:SABSW)

0.0282 -0.0008 (-2.76%)
Streaming Delayed Price Updated: 1:18 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,000
Open 0.0399
Bid (Size) 0.0282 (17)
Ask (Size) 0.0545 (21)
Prev. Close 0.0290
Today's Range 0.0280 - 0.0399
52wk Range 0.0205 - 0.1800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SAB BIO Highlights Data in Multiple Presentations at EASD
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-54.5%
-54.5%
1 Month
+4.8%
+4.8%
3 Month
-19.2%
-19.2%
6 Month
+16.5%
+16.5%
1 Year
-48.2%
-48.2%

More News

Read More
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Oversubscribed $175 Million Private Placement
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Reports Full Year 2024 Operating and Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Appoints Lucy To as Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAb Biotherapeutics Rebrands as SAB BIO
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Departure of Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Provides SAB-142 Trial Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at INNODIA Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is SAB Biotherapeutics, Inc. - Warrant publicly traded?
Yes, SAB Biotherapeutics, Inc. - Warrant is publicly traded.
What exchange does SAB Biotherapeutics, Inc. - Warrant trade on?
SAB Biotherapeutics, Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for SAB Biotherapeutics, Inc. - Warrant?
The ticker symbol for SAB Biotherapeutics, Inc. - Warrant is SABSW on the Nasdaq Stock Market
What is the current price of SAB Biotherapeutics, Inc. - Warrant?
The current price of SAB Biotherapeutics, Inc. - Warrant is 0.0282
When was SAB Biotherapeutics, Inc. - Warrant last traded?
The last trade of SAB Biotherapeutics, Inc. - Warrant was at 10/24/25 01:18 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.